Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose study of HP-6050 in healthy adults
jRCT2031220092Phase 1Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HP-6050, sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Pharmacokinetic parameters and Adverse events. Started May 2022; status: completed.
02
Drugs
HP-6050
Beyond the preview
Go deeper on jRCT2031220092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220092.